Speaker Profile
M.D., Ph.D., Associate Professor of Radiation Oncology, Mass General Brigham
Biography
Dr. David Miyamoto is a physician scientist in the Krantz Family Center for Cancer Research at the Mass General Brigham Cancer Institute and Harvard Medical School. His translational research efforts focus on the development of novel biomarkers to guide bladder and prostate cancer therapy and improve the individualized care of each patient, with an emphasis on liquid biopsies. He has authored over 60 publications in peer-reviewed scientific journals including Science, Cell, Cancer Discovery, Nature Communications, and Lancet Oncology. His research has been supported by grants from the NIH, U.S. Department of Defense, Prostate Cancer Foundation, and Radiation Oncology Institute. Dr. Miyamoto is also a board-certified radiation oncologist specializing in treating patients with genitourinary malignancies. After receiving his AB (Chemistry), MD, and PhD (Cell and Developmental Biology) degrees from Harvard University, he completed his internship in Internal Medicine at the Brigham Women's Hospital and his residency in the Harvard Radiation Oncology Program.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Adrian Lee, University of Pittsburgh
PMWC Award Ceremony
• Dennis J. Slamon, UCLA
• Arul M. Chinnaiyan, University of Michigan
Keynote
• Dennis J. Slamon, UCLA
Keynote: From Cancer Drivers to Clinical Decisions – Transforming Tumor Genomics into Therapy Guidance
• Arul M. Chinnaiyan, University of Michigan
Serial ctDNA-Guided Therapy Switching (SERENA-6 & Beyond)
• Chair: Adrian Lee, UPMC
• Pedram Razavi, MSK
• Minetta Liu, Natera
Neoadjuvant to Adjuvant MRD: How Early Is Early Enough?
• Chair: Angela DeMichele, University of Pennsylvania
• Halla Nimeiri, Tempus
• Aparna Parikh, Harvard
• Minetta Liu, Natera
• Christopher Lieu, University of Colorado
Multi-Omics Monitoring Beyond Variants: Methylation, Fragmentomics, EV/ctRNA
• David T. Miyamoto, Massachusetts General Hospital
• Maximilian Diehn, Stanford
• Daniel De Carvalho, University of Toronto
• Arul M. Chinnaiyan, University of Michigan
Rapid MRD to Treatment Decisions: Standardized ctDNA at Scale
• Chair: Luca Quagliata, ThermoFisher
From Validation to Payment: Coverage Pathways That Work
• Chair: Mark Stewart, Friends of Cancer Research
• Hilary Gee Goeckner, American Cancer Society
• Sally Werner, Cancer Support Community
• Gabriel A. Bien-Willner, Palmetto GBA
